File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1093/cid/ciab625
- Scopus: eid_2-s2.0-85124577993
- PMID: 34245250
- WOS: WOS:000754315700025
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Reducing influenza virus transmission: the value of antiviral treatment
Title | Reducing influenza virus transmission: the value of antiviral treatment |
---|---|
Authors | |
Keywords | influenza transmission antiviral baloxavir oseltamivir |
Issue Date | 2022 |
Publisher | Oxford University Press, published in association with Clinical Infectious Diseases. The Journal's web site is located at http://www.oxfordjournals.org/our_journals/cid/ |
Citation | Clinical Infectious Diseases, 2022, v. 74 n. 3, p. 532-540 How to Cite? |
Abstract | Prompt antiviral treatment has the potential to reduce influenza virus transmission to close contacts, but rigorous data on the magnitude of treatment effects on transmission are limited. Animal model data indicate that rapid reductions in viral replication after antiviral treatment reduce the risk of transmission. Observational and clinical trial data with oseltamivir and other neuraminidase inhibitors indicate that prompt treatment of household index patients seems to reduce the risk of illness in contacts, although the magnitude of the reported effects has varied widely across studies. In addition, the potential risk of transmitting drug-resistant variants exists with all approved classes of influenza antivirals. A controlled trial examining baloxavir treatment efficacy to reduce transmission, including the risk of transmitting virus with reduced baloxavir susceptibility, is currently in progress. If reduced transmission risk is confirmed, modeling studies indicate that early treatment could have major epidemiologic benefits in seasonal and pandemic influenza. |
Persistent Identifier | http://hdl.handle.net/10722/301643 |
ISSN | 2023 Impact Factor: 8.2 2023 SCImago Journal Rankings: 3.308 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hayden, FG | - |
dc.contributor.author | Asher, J | - |
dc.contributor.author | Cowling, BJ | - |
dc.contributor.author | Hurt, AC | - |
dc.contributor.author | Ikematsu, H | - |
dc.contributor.author | Kuhlbusch, K | - |
dc.contributor.author | Lemenuel-Diot, A | - |
dc.contributor.author | Du, Z | - |
dc.contributor.author | Meyers, LA | - |
dc.contributor.author | Piedra, PA | - |
dc.contributor.author | Takazon, T | - |
dc.contributor.author | Yen, H | - |
dc.contributor.author | Monto, AS | - |
dc.date.accessioned | 2021-08-09T03:42:03Z | - |
dc.date.available | 2021-08-09T03:42:03Z | - |
dc.date.issued | 2022 | - |
dc.identifier.citation | Clinical Infectious Diseases, 2022, v. 74 n. 3, p. 532-540 | - |
dc.identifier.issn | 1058-4838 | - |
dc.identifier.uri | http://hdl.handle.net/10722/301643 | - |
dc.description.abstract | Prompt antiviral treatment has the potential to reduce influenza virus transmission to close contacts, but rigorous data on the magnitude of treatment effects on transmission are limited. Animal model data indicate that rapid reductions in viral replication after antiviral treatment reduce the risk of transmission. Observational and clinical trial data with oseltamivir and other neuraminidase inhibitors indicate that prompt treatment of household index patients seems to reduce the risk of illness in contacts, although the magnitude of the reported effects has varied widely across studies. In addition, the potential risk of transmitting drug-resistant variants exists with all approved classes of influenza antivirals. A controlled trial examining baloxavir treatment efficacy to reduce transmission, including the risk of transmitting virus with reduced baloxavir susceptibility, is currently in progress. If reduced transmission risk is confirmed, modeling studies indicate that early treatment could have major epidemiologic benefits in seasonal and pandemic influenza. | - |
dc.language | eng | - |
dc.publisher | Oxford University Press, published in association with Clinical Infectious Diseases. The Journal's web site is located at http://www.oxfordjournals.org/our_journals/cid/ | - |
dc.relation.ispartof | Clinical Infectious Diseases | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | influenza | - |
dc.subject | transmission | - |
dc.subject | antiviral | - |
dc.subject | baloxavir | - |
dc.subject | oseltamivir | - |
dc.title | Reducing influenza virus transmission: the value of antiviral treatment | - |
dc.type | Article | - |
dc.identifier.email | Cowling, BJ: bcowling@hku.hk | - |
dc.identifier.email | Du, Z: zwdu@hku.hk | - |
dc.identifier.email | Yen, H: hyen@hku.hk | - |
dc.identifier.authority | Cowling, BJ=rp01326 | - |
dc.identifier.authority | Du, Z=rp02777 | - |
dc.identifier.authority | Yen, H=rp00304 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1093/cid/ciab625 | - |
dc.identifier.pmid | 34245250 | - |
dc.identifier.pmcid | PMC8834654 | - |
dc.identifier.scopus | eid_2-s2.0-85124577993 | - |
dc.identifier.hkuros | 323983 | - |
dc.identifier.volume | 74 | - |
dc.identifier.issue | 3 | - |
dc.identifier.spage | 532 | - |
dc.identifier.epage | 540 | - |
dc.identifier.isi | WOS:000754315700025 | - |
dc.publisher.place | United States | - |